Plasma Cholesterol Regulates Soluble Cell Adhesion Molecule Expression in Familial Hypercholesterolemia

Sampietro, Tiziana; Tuoni, M.; Ferdeghini, M; Ciardi, Antonio; Marraccini, Paolo; Prontera, Concetta; Sassi, Guido; Taddei, Marco; Bionda, A.

doi:10.1161/01.cir.96.5.1381

Cited by 102 publications

(74 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LDL-apheresis, consistent with previous reports, induced a reduction of circulating TC, LDL-C, apoB, HDL-C, and apoA-I ( 11,24 ). Two days after the procedure, all lipid parameters but HDL-C and apoA-I were still low; SR-BIand AD-mediated CEC were signifi cantly reduced immediately after LDL-apheresis and, in parallel with HDL-C and apoA-I plasma levels, returned to pretreatment values after two days ( Figs.…”

Section: Patient Serum Macrophage Clc Before Immediately After and supporting

confidence: 92%

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

Adorni

Zimetti

Puntoni

et al. 2012

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

Section: Patient Serum Macrophage Clc Before Immediately After and supporting

confidence: 92%

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

Adorni

Zimetti

Puntoni

et al. 2012

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

“…In addition, lipid apheresis in patients with familial hypercholesterolemia has been associated with concomitant decreases in circulating adhesion molecule levels. 32 Although small clinical studies 10,33 have suggested that increased levels of adhesion molecules are found in patients with dyslipidemia, a recent report from a large cohort of patients derived from the Atherosclerosis Risk in Communities study failed to demonstrate any significant association between sICAM-1 with triglycerides, total cholesterol, LDL-C, and HDL-C levels. 11 The significant associations between sICAM-1 with triglycerides and HDL-C levels observed in our study, however, support the concept that lipid metabolism may play a role in the modulation of cellular adhesion molecules.…”

Section: Rohde Et Al Sicam-1 and Cardiovascular Risk Factorsmentioning

confidence: 99%

Cross-Sectional Study of Soluble Intercellular Adhesion Molecule-1 and Cardiovascular Risk Factors in Apparently Healthy Men

Rohde

Hennekens

Ridker

1999

ATVB

147

View full text Add to dashboard Cite

Abstract-An elevated plasma concentration of the soluble intercellular adhesion molecule-1 (sICAM-1) is associated with increased risk for future coronary events. However, data exploring the interrelations of sICAM-1 with known cardiovascular risk factors are sparse. We determined sICAM-1 levels in 948 middle-aged men with no prior history of cardiovascular disease. sICAM-1 levels increased with age (PϽ0.001) and were significantly associated with smoking (PϽ0. Key Words: adhesion molecules Ⅲ inflammation Ⅲ risk factors Ⅲ atherosclerosis C ellular adhesion molecules mediate the attachment and transmigration of leukocytes across the endothelial surface, and are hypothesized to play an important role in the initiation of atherosclerosis. 1 Focal expression of adhesion molecules has been demonstrated in atherosclerotic lesions, 2-4 precedes leukocyte infiltration, 5,6 and seems to be mediated in part by modified lipoproteins or their constituents. 7 Several small studies have demonstrated that plasma concentrations of soluble intercellular adhesion molecule-1 (sICAM-1) are elevated in atherosclerotic syndromes, 8 -12 and 2 recent prospective studies indicate that elevated baseline levels of sICAM-1 are associated with increased risk for future coronary events. 11,13 However, despite these provocative data, little is known about potential relations between circulating adhesion molecules and established cardiovascular risk factors.We explored potential associations between the soluble adhesion molecule sICAM-1 and a series of lipid and nonlipid cardiovascular risk factors among 948 apparently healthy men participating in the Physicians' Health Study. Specifically, we evaluated for evidence of association between sICAM-1 levels and age, smoking status, blood pressure, alcohol use, exercise frequency, body mass index, total cholesterol, HDL cholesterol (HDL-C), triglycerides, Lp(a), fibrinogen, tissue-type plasminogen activator antigen, and total homocysteine levels. MethodsWe evaluated sICAM-1 levels in a cross-section of apparently healthy middle-aged men participating in the Physician's Health Study. In brief, the Physician's Health Study was a randomized, double-blind, placebocontrolled 2ϫ2 factorial design trial of aspirin and ␤-carotene among US male physicians aged 40 to 84 years. 14 Exclusion criteria included a history of myocardial infarction, stroke, or transient ischemic attack; cancer; current renal or liver disease; peptic ulcer or gout; contraindication to aspirin consumption; current use of aspirin, other plateletactive drugs, or nonsteroidal anti-inflammatory agents; and current use of vitamin A or ␤-carotene supplement.As described elsewhere, 13 eligible participants were asked to provide baseline blood plasma samples. Kits including edetic acid tubes and plastic collection vials were sent to each doctor along with instructions for blood drawing. Participants were asked to have their blood drawn and centrifuged, and have the plasma returned (accompanied by a cold pack) by overnight courier. Participa...

show abstract

“…Low-density lipoprotein (LDL) apheresis is a potentially useful treatment for conventional therapy-resistant hypercholesterolemic patients with coronary artery disease and PAD. 1,2 Previously, it was shown that a single LDL apheresis session enhanced the peripheral microcirculation, probably by increasing the production of nitric oxide (NO) and bradykinin, 3 reducing blood viscosity and adhesion molecules, 4 and inducing endothelium-dependent vasodilatation. 5 However, the precise molecular mechanism of the long-term effects of LDL apheresis on the improvement of the peripheral circulation remains unclear and warrants further investigation.…”

mentioning

confidence: 99%

Sustained Inhibition of Oxidized Low-Density Lipoprotein Is Involved in the Long-Term Therapeutic Effects of Apheresis in Dialysis Patients

Tsurumi‐Ikeya

Tamura

Azuma

et al. 2010

ATVB

View full text Add to dashboard Cite

Objective-Low-density lipoprotein (LDL) apheresis is a potential therapy for conventional therapy-resistant peripheral artery disease. In the present study, we examined the chronic effects of LDL apheresis on clinical parameters in vivo and endothelial cell functions in vitro in hemodialysis patients who had the complication of peripheral artery disease. Methods and Results-Twenty-five patients were enrolled, and the responses of 19 patients to LDL apheresis were analyzed. Patients were classified into 2 groups according to change in ankle-brachial pressure index (ABI) after treatment: patients with improved ABI (responders, nϭ10) and patients with worsened ABI (nonresponders, nϭ9). In the responders, apheresis resulted in a long-term reduction of circulating levels of oxidized LDL, C-reactive protein, and fibrinogen. In human umbilical vein endothelial cells (HUVECs), the serum from the responders increased expression of activated endothelial nitric oxide synthase protein and proliferative activity. Key Words: atherosclerosis Ⅲ endothelium Ⅲ nitric oxide synthase Ⅲ oxidized lipids Ⅲ peripheral arterial disease Ⅲ lipoproteins Ⅲ oxidative stress C ardiovascular disease is the primary cause of death in patients with end-stage renal disease. Patients on dialysis are reported to have a 10 -20-fold greater risk of cardiovascular disease-associated mortality than the general population after stratification for age, gender, race, and the presence or absence of diabetes. Patients undergoing dialysis have many of the risk factors for atherosclerosis, such as hypertension, dyslipidemia, and disturbed calcium-phosphate metabolism, and, indeed, they commonly experience severe atherosclerosis, including peripheral artery disease (PAD). Low-density lipoprotein (LDL) apheresis is a potentially useful treatment for conventional therapy-resistant hypercholesterolemic patients with coronary artery disease and PAD. 1,2 Previously, it was shown that a single LDL apheresis session enhanced the peripheral microcirculation, probably by increasing the production of nitric oxide (NO) and bradykinin, 3 reducing blood viscosity and adhesion molecules, 4 and inducing endothelium-dependent vasodilatation. 5 However, the precise molecular mechanism of the long-term effects of LDL apheresis on the improvement of the peripheral circulation remains unclear and warrants further investigation.We undertook the present study to investigate the shortand long-term effects of LDL apheresis on clinical and laboratory parameters in vivo and vascular endothelial cell function in vitro, in hemodialysis patients with PAD, and to identify factors related to the improvement of the peripheral circulation by LDL apheresis. Methods Patients and Study DesignThe study protocol was approved by the Human Ethics Committee of Yokohama City University Hospital. A total of 25 consecutive hemodialysis patients with leg impairments and ankle-

show abstract

Plasma Cholesterol Regulates Soluble Cell Adhesion Molecule Expression in Familial Hypercholesterolemia

Cited by 102 publications

References 16 publications

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

Cross-Sectional Study of Soluble Intercellular Adhesion Molecule-1 and Cardiovascular Risk Factors in Apparently Healthy Men

Sustained Inhibition of Oxidized Low-Density Lipoprotein Is Involved in the Long-Term Therapeutic Effects of Apheresis in Dialysis Patients

Contact Info

Product

Resources

About